EUVIMEDEUVIMED entdecken
Crossref

Cyclo(Val-Pro) and cyclo(Phe-Phe) alleviate MASLD via distinct CCR2- and ADCY7-associated pathways

Jun Zhou, Haojie Jin, Yifan Zheng, Kunying Ding, Yu Long, Chenjie Yu, Yueran Zhang, Fen Zhuge, Minhua Chen, Zhengwei Fu, Yinhua Ni

Life Sciences · 2026

DOI: 10.1016/j.lfs.2026.124669 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Sciences, 2026. Verfasst von Jun Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, 310032, China. Hauptthemen laut MEDLINE: Receptors, CCR2, Fatty Liver, Adenylyl Cyclases, Peptides, Cyclic. Die Arbeit nennt 84 Literaturangaben. Gefördert von: National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD), hallmarked by hepatic metabolic disorders and chronic inflammation, is a growing global public health threat with limited approved pharmacological options. Natural cyclodipeptides exhibit favorable metabolic stability and bioactivity profiles, making them ideal molecules for drug discovery in metabolic diseases; however, their roles and mechanisms in MASLD remain poorly defined. Here, we investigated the protective effects of cyclo(Val-Pro) and cyclo(Phe-Phe), two bioactive cyclodipeptides previously identified in hydrolyzed chicken meat extract (HCE), against MASLD. Administration of both cyclodipeptides effectively ameliorated metabolic disturbance and hepatic inflammation in high-fat diet-induced MASLD mice, and mitigated lipopolysaccharide-triggered acute inflammation in a complementary in vivo model. Liver transcriptomic analysis revealed that the two cyclodipeptides significantly modulated the hepatic chemokine signaling pathway in MASLD mice. Mechanistically, both cyclodipeptides reduced hepatic CD11b- and F4/80-associated signals and modulated macrophage-associated pro-inflammatory and anti-inflammatory marker expression in vivo and in vitro. Further validation using molecular docking, target inhibitor intervention, drug affinity responsive target stability, cellular thermal shift assay, site-directed mutagenesis, and gene knockout approaches supported that cyclo(Val-Pro) regulated the expression of macrophage CC chemokine receptor type 2 (CCR2), while cyclo(Phe-Phe) modulated adenylyl cyclase 7 (ADCY7), an upstream chemokine signaling regulator, to block downstream inflammatory cascades. Collectively, our findings support further investigation of these two cyclodipeptides and suggest that CCR2- and ADCY7-associated pathways may contribute to their effects in MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CCR2Fatty LiverAdenylyl CyclasesPeptides, CyclicAnimalsMiceMaleMice, Inbred C57BLSignal TransductionInflammationLiverDiet, High-Fat

Stichwörter der Autor:innen

ADCY7CCR2Cyclo(Phe-Phe)Cyclo(Val-Pro)InflammationMASLD

Substanzen

Receptors, CCR2Adenylyl CyclasesPeptides, CyclicCcr2 protein, mouse

Autor:innen und Institutionen

  • College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, 310032, China.
  • College of Pharmacy, Zhejiang University of Technology, Hangzhou, 310032, China.
  • Institute of Translational Medicine, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, 310015, China.
  • Emergency and Critical Care Center, Intensive Care Unit, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, 310014, China.
  • College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, 310032, China. Electronic address: shali0145@zjut.edu.cn.

Förderung

  • National Key Research and Development Program of China

Zitieren

APA

Zhou, J., Jin, H., Zheng, Y., Ding, K., Long, Y., Yu, C., Zhang, Y., Zhuge, F., Chen, M., Fu, Z., & Ni, Y. (2026). Cyclo(Val-Pro) and cyclo(Phe-Phe) alleviate MASLD via distinct CCR2- and ADCY7-associated pathways. Life Sciences. https://doi.org/10.1016/j.lfs.2026.124669

Vancouver

Zhou J, Jin H, Zheng Y, Ding K, Long Y, Yu C, et al. Cyclo(Val-Pro) and cyclo(Phe-Phe) alleviate MASLD via distinct CCR2- and ADCY7-associated pathways. Life Sciences. 2026. doi:10.1016/j.lfs.2026.124669

BibTeX
@article{Zhou2026,
  author = {Zhou, Jun and Jin, Haojie and Zheng, Yifan and Ding, Kunying and Long, Yu and Yu, Chenjie and Zhang, Yueran and Zhuge, Fen and Chen, Minhua and Fu, Zhengwei and Ni, Yinhua},
  title = {Cyclo(Val-Pro) and cyclo(Phe-Phe) alleviate MASLD via distinct CCR2- and ADCY7-associated pathways},
  journal = {Life Sciences},
  year = {2026},
  doi = {10.1016/j.lfs.2026.124669}
}
Kostenlos starten →